150 related articles for article (PubMed ID: 37535949)
1. Assessment of Human Papillomavirus Non-16/18, Type-Specific Risk for Cervical Intraepithelial Neoplasia Grade 3 or Worse Among Women With Cervical Atypical Glandular Cells.
Yilmaz E; Lagheden C; Ghaderi M; Wang J; Dillner J; Elfström KM
Obstet Gynecol; 2023 Sep; 142(3):679-687. PubMed ID: 37535949
[TBL] [Abstract][Full Text] [Related]
2. Atypical glandular cells and development of cervical cancer: Population-based cohort study.
Norman I; Yilmaz E; Hjerpe A; Hortlund M; Elfström KM; Dillner J
Int J Cancer; 2022 Dec; 151(11):2012-2019. PubMed ID: 36029205
[TBL] [Abstract][Full Text] [Related]
3. Human papillomavirus DNA detection and histological findings in women referred for atypical glandular cells or adenocarcinoma in situ in their Pap smears.
Derchain SF; Rabelo-Santos SH; Sarian LO; Zeferino LC; de Oliveira Zambeli ER; do Amaral Westin MC; de Angelo Andrade LA; Syrjänen KJ
Gynecol Oncol; 2004 Dec; 95(3):618-23. PubMed ID: 15581973
[TBL] [Abstract][Full Text] [Related]
4. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence.
Kjær SK; Frederiksen K; Munk C; Iftner T
J Natl Cancer Inst; 2010 Oct; 102(19):1478-88. PubMed ID: 20841605
[TBL] [Abstract][Full Text] [Related]
5. Five-year risk of recurrence after treatment of CIN 2, CIN 3, or AIS: performance of HPV and Pap cotesting in posttreatment management.
Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Gage JC; Kinney WK
J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S78-84. PubMed ID: 23519309
[TBL] [Abstract][Full Text] [Related]
6. Value of HPV-DNA test in women with cytological diagnosis of atypical glandular cells (AGC).
Zeferino LC; Rabelo-Santos SH; Villa LL; Sarian LO; Costa MC; do Amaral Westin MC; de Ângelo-Andrade LA; Derchain S
Eur J Obstet Gynecol Reprod Biol; 2011 Nov; 159(1):160-4. PubMed ID: 21680079
[TBL] [Abstract][Full Text] [Related]
7. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
8. The IMproving Primary Screening And Colposcopy Triage trial: human papillomavirus, cervical cytology, and histopathologic results from the baseline and 1-year follow-up phase.
Safaeian M; Wright TC; Stoler MH; Ranger-Moore J; Rehm S; Aslam S; Fang Q; Volkir P; Ridder R
Am J Obstet Gynecol; 2021 Sep; 225(3):278.e1-278.e16. PubMed ID: 33852886
[TBL] [Abstract][Full Text] [Related]
9. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial.
Rijkaart DC; Berkhof J; Rozendaal L; van Kemenade FJ; Bulkmans NW; Heideman DA; Kenter GG; Cuzick J; Snijders PJ; Meijer CJ
Lancet Oncol; 2012 Jan; 13(1):78-88. PubMed ID: 22177579
[TBL] [Abstract][Full Text] [Related]
10. The combined finding of HPV 16, 18, or 45 and cytologic Atypical Glandular Cells (AGC) indicates a greatly elevated risk of in situ and invasive cervical adenocarcinoma.
Schiffman M; Mirabello L; Egemen D; Befano B; Xiao Y; Wentzensen N; Raine-Bennett T; Nayar R; Cheung LC; Rositch A; Beaty T; Perkins RB; de Sanjose S; Lorey T; Castle PE; Burk RD
Gynecol Oncol; 2023 Jul; 174():253-261. PubMed ID: 37243996
[TBL] [Abstract][Full Text] [Related]
11. Outcome and associated factors of high-risk human papillomavirus infection without cervical lesions.
Feng T; Cheng B; Sun W; Yang Y
BMC Womens Health; 2023 Nov; 23(1):599. PubMed ID: 37957634
[TBL] [Abstract][Full Text] [Related]
12. [Clinical value of p16
Song FB; Du H; Xiao AM; Wang C; Huang X; Yan PS; Liu ZH; Qu XF; Belinson JEROMEL; Wu RF
Zhonghua Fu Chan Ke Za Zhi; 2020 Nov; 55(11):784-790. PubMed ID: 33228350
[No Abstract] [Full Text] [Related]
13. Use of human papillomavirus testing in the management of atypical glandular cells.
Schnatz PF; Sharpless KE; O'Sullivan DM
J Low Genit Tract Dis; 2009 Apr; 13(2):94-101. PubMed ID: 19387129
[TBL] [Abstract][Full Text] [Related]
14. Three-year risk of high-grade CIN for women aged 30 years or older who undergo baseline Pap cytology and HPV co-screening.
Guo M; Khanna A; Wang J; Dawlett MA; Kologinczak TL; Lyons GR; Bassett RL; Sneige N; Gong Y; Bevers TB
Cancer Cytopathol; 2017 Aug; 125(8):644-651. PubMed ID: 28498639
[TBL] [Abstract][Full Text] [Related]
15. [Evaluation of CIN2+ /CIN3+ risk of different HPV subtypes infection combined with abnormal cytology status].
Luo HX; Du H; Liu ZH; Zhang LJ; Wang C; Wu RF
Zhonghua Zhong Liu Za Zhi; 2018 Mar; 40(3):232-238. PubMed ID: 29575846
[No Abstract] [Full Text] [Related]
16. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.
Leinonen M; Nieminen P; Kotaniemi-Talonen L; Malila N; Tarkkanen J; Laurila P; Anttila A
J Natl Cancer Inst; 2009 Dec; 101(23):1612-23. PubMed ID: 19903804
[TBL] [Abstract][Full Text] [Related]
17. Type-specific oncogenic human papillomavirus infection in high grade cervical disease in New Zealand.
Simonella LM; Lewis H; Smith M; Neal H; Bromhead C; Canfell K
BMC Infect Dis; 2013 Mar; 13():114. PubMed ID: 23452957
[TBL] [Abstract][Full Text] [Related]
18. Prediction of recurrence after treatment for high-grade cervical intraepithelial neoplasia: the role of human papillomavirus testing and age at conisation.
Verguts J; Bronselaer B; Donders G; Arbyn M; Van Eldere J; Drijkoningen M; Poppe W
BJOG; 2006 Nov; 113(11):1303-7. PubMed ID: 16978225
[TBL] [Abstract][Full Text] [Related]
19. [Performance of vaginal self-sampling high-risk HPV genotyping as primary and combining cytology or viral load as secondary in cervical cancer screening].
Guo CL; Luo HX; Wang C; Qu XF; Yang B; Belinson JL; Du H; Wu RF
Zhonghua Fu Chan Ke Za Zhi; 2021 Apr; 56(4):271-279. PubMed ID: 33902239
[No Abstract] [Full Text] [Related]
20. Risk of high-grade lesions after atypical glandular cells in cervical screening: a population-based cohort study.
Norman I; Hjerpe A; Dillner J
BMJ Open; 2017 Dec; 7(12):e017070. PubMed ID: 29247086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
